Leading Indian pharmaceutical companies are shifting strategy away from the US generics market, which faces severe pricing pressure and future tariff risks. While Sun Pharma and Aurobindo Pharma reported strong revenue growth, Dr. Reddy's profits dipped significantly due to specific product challenges. This trend underscores a broad industry pivot toward stabilizing income through domestic and emerging market expansion.
Major Indian pharmaceutical companies are navigating a shifting landscape as they pivot away from the US generics market, which has traditionally been a primary source of profit. The first quarter of the 2026-27 financial year shows a clear trend: companies are increasingly relying on domestic sales and emerging markets to balance out volatility and pricing pressure in the US.
Performance Divergence in Q1 FY27
Sun Pharmaceutical Industries Ltd. maintained a steady path, reporting a 10% year-on-year increase in revenue to ₹15,184 crore. A key detail in their performance is the 9.7% decline in US formulations. However, the company offset this by growing its Indian formulations business by 16% to ₹5,475 crore and expanding its global innovative medicines segment. This diversification suggests a strategic effort to move beyond pure generic price-war models.
Aurobindo Pharma reported the strongest performance among the three, with revenue rising 16.3% to ₹9,150 crore and net profit increasing by 25% to ₹1,032 crore. The company successfully improved its profit margins to 21%, indicating better control over operational efficiency despite the broader sector challenges.
In contrast, Dr. Reddy's Laboratories highlighted the risks of being heavily exposed to the US market. The company’s net profit fell 69% to ₹444 crore. This decline was primarily driven by the absence of sales from a previously successful product, lenalidomide, and a one-time ₹240-crore provision related to quality concerns for its semaglutide API. This incident serves as a reminder of the regulatory and operational hurdles that can suddenly impact profitability in the generics business.
The Looming Tariff Risk
The pivot toward India and emerging markets is not just about current pricing pressure; it is also a preparation for long-term geopolitical risks. A proposed US tariff plan aims to heavily tax imported generic drugs starting in 2028. While there is no immediate duty on these imports until July 2028, the proposed schedule—rising to 100% in 2028 and 200% from 2029—creates a long-term threat to the viability of the export-heavy model that Indian firms have relied on for decades.
Investors should monitor how these companies continue to reallocate resources. For the coming quarters, the key monitorables are the sustainability of domestic demand, the ability to maintain profit margins amid rising raw material and logistics costs, and any updates regarding regulatory compliance in international markets. As companies try to reduce their reliance on US generics, their success will likely depend on how effectively they can scale their higher-value, innovative product offerings in India and other developing economies.